Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 2,103 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable saline Clear all

Conditions: HIV Infections
Interventions: gp145 C.6980 Vaccine, Placebo, Aluminum Hydroxide Adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia, Ulcers
Interventions: HGF plasmid, Placebo; Genetic
Lead sponsor: AnGes USA, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 4
States / cities: Pensacola, Florida • Indianapolis, Indiana • Boston, Massachusetts + 1 more

Conditions: Platysma Prominence
Interventions: OnabotulinumtoxinA, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Vista, California + 16 more

Conditions: Corneal Neovascularization, Corneal Graft Failure
Interventions: Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel; Drug
Lead sponsor: Reza Dana, MD; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts • New York, New York

Conditions: Infection, Human Immunodeficiency Virus
Interventions: 744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more

Conditions: Pancreatic Cancer
Interventions: Synthetic Human Secretin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV Vaccine (GSK3844766A) unadjuvanted low dose, RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B, RSV Vaccine (GSK3844766A) unadjuvanted medium dose, RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B, RSV Vaccine (GSK3844766A) unadjuvanted high dose, RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B, Placebo (Saline solution); Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,053 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 18
States / cities: Jacksonville, Florida • Miami, Florida • Stockbridge, Georgia + 15 more

Conditions: Vulvovaginal Candidiasis
Interventions: NDV-3A, NDV-3, Placebo; Biological
Lead sponsor: NovaDigm Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more

Conditions: Knee Osteoarthritis
Interventions: Micronized dHACM, Saline; Biological · Drug
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 17
States / cities: Birmingham, Alabama • Tempe, Arizona • La Mesa, California + 14 more

Conditions: AIDS, HIV
Interventions: Fluarix, Pneumovax, Placebo; Biological · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Knee Arthropathy
Interventions: Bupivacaine with epinephrine, Methylprednisolone, Cefazolin, 8 MHz. Chiba needle, Bupivacaine with Dexamethasone, Bupivacaine 25cc, Bupivacaine 20cc, Dexamethasone; Drug · Device
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Congestive Heart Failure
Interventions: Nesiritide, Placebo, Saline; Drug
Lead sponsor: Horng Chen; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Alopecia, Androgenetic
Interventions: Puregraft System, Celution System, Kerastem Therapy, Liposuction; Device · Procedure
Lead sponsor: Kerastem Technologies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: Los Angeles, California • Miami, Florida • Highland Park, New Jersey + 1 more

Conditions: Delayed Graft Function, Other Complication of Kidney Transplant
Interventions: I5NP, Saline; Drug
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 33
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 22 more

Conditions: Post-operative Surgical Pain
Interventions: Nerve Block with ropivicaine 0.5% Injectable Solution, Nerve Block with Placebo sham control of 0.9% Normal Saline; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Blepharospasm
Interventions: incobotulinumtoxinA (Xeomin), Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Injection Site Irritation, Injection Site Bruising, Injection Site Discomfort, Benzoic Acid Adverse Reaction, Anesthesia, Local
Interventions: Sodium Chloride 0.9% Inj, Bacteriostatic Sodium Chloride 0.9 % INJECTION VIAL (ML); Drug
Lead sponsor: Jeffrey Alan Klein, MD; Industry
Eligibility: 16 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Juan Capistrano, California

Conditions: Heterozygous Familial Hypercholesterolemia, Elevated Cholesterol
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 10
States / cities: Mission Viejo, California • Newport Beach, California • Stanford, California + 7 more

Conditions: Healthy
Interventions: CD101 IV, Placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Advanced Or Metastatic Merkel Cell Carcinoma
Interventions: IFx-Hu2.0, Placebo, Pembrolizumab; Drug
Lead sponsor: TuHURA Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 18
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 15 more

Conditions: Neuropathic Pain From Lumbosacral Radiculopathy
Interventions: KLS-2031, Placebo; Drug · Other
Lead sponsor: Kolon Life Science; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Familial Hypercholesterolemia - Homozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri + 1 more

Conditions: Pain, Postoperative, Opioid Use
Interventions: Liposomal bupivacaine, TAP block, Deposition of saline; Drug · Procedure
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Rabies
Interventions: Rabies vaccine, Placebo; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Syracuse, New York

Search by objective public record fields.

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the Knee

Perturbing of HIV Reservoir With Immune Stimulation

Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)

Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction

STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia

I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation

Regional Anesthesia (Supra-Orbital and Infra-Orbital Nerve Block) (SION) for Pain Management in Trans-sphenoidal Hypophysectomy

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

Comparison of Subcutaneous Injection of Normal Saline and Bacteriostatic Saline

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

A Single Ascending Dose Study of CD101 IV in Healthy Subjects

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Stopping Opioid Overuse in Obstetrics to Halt Exposure Trial

Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis